2. Search Result
Search Result
Results for "

hypotensive effects

" in MedChemExpress (MCE) Product Catalog:

16

Inhibitors & Agonists

3

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W001940
    DL-m-Tyrosine

    		Others Cardiovascular Disease
    DL-m-Tyrosine shows effects on Arabidopsis root growth. Carbidopa combination with DL-m-tyrosine shows a potent hypotensive effect .
    DL-m-Tyrosine
  • HY-121653
    Flesinoxan

    		5-HT Receptor Neurological Disease
    Flesinoxan is a hypotensive agent and a potent, high affinity and selective 5-hydroxytryptamine1A (5-HT1A) receptor agonist with an EC50 value of 24 nM. Flesinoxan also has effective anxiolytic/antidepressant effects .
    Flesinoxan
  • HY-146650
    LpxC-IN-9

    		Bacterial Infection Cardiovascular Disease
    LpxC-IN-9 (compound 19) is a potent LpxC inhibitor. LpxC-IN-9 has antibacterial and hypotensive effects . LpxC-IN-9 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    LpxC-IN-9
  • HY-116158
    Oosponol

    		Dopamine β-hydroxylase Fungal Infection Cardiovascular Disease
    Oosponol is a dopamine beta-hydroxylase inhibitor exhibiting hypotensive effects.Oospongol has strong antifungal activity against many antagonistic fungi .
    Oosponol
  • HY-121550
    ME3221

    		Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    ME3221 is an angiotensin AT1 receptor antagonist that effectively antagonizes the pressor response to angiotensin II in rats and marmosets without affecting the hypotensive response to bradykinin. It demonstrates potent antihypertensive effects in renal hypertensive rats and spontaneously hypertensive rats (SHR), with efficacy comparable to or better than losartan in vivo. ME3221's repeated administration in SHR results in sustained and stable hypotensive effects without affecting heart rate, indicating its potential for treating both renal and essential hypertension similarly to losartan .
    ME3221
  • HY-120405
    RS-12254

    		Others Others
    RS-12254 is a compound with hypotensive, diuretic and sympathostatic effects, and has the activity of regulating blood pressure, water and salt metabolism and sympathetic nerve activity. RS-12254 can lower blood pressure, reduce plasma norepinephrine levels, has diuretic and natriuretic effects, and has sympathostatic properties.
    RS-12254
  • HY-W001940S
    DL-m-Tyrosine-d3

    		Isotope-Labeled Compounds Cardiovascular Disease
    DL-m-Tyrosine-d3 is the deuterium labeled DL-m-Tyrosine. DL-m-Tyrosine shows effects on Arabidopsis root growth. Carbidopa combination with DL-m-tyrosine shows a potent hypotensive effect[1][2].
    DL-m-Tyrosine-d3
  • HY-N4209
    3α-Dihydrocadambine

    		Others Cardiovascular Disease
    3α-Dihydrocadambine is a natural product isolated from the heartwoods of Anthocephalus cadamba.3α-Dihydrocadambine exhibits dose-dependent hypotensive and anti-hypertensive effects in anesthetized normotensive rats and in conscious spontaneously hypertensive rats .
    3α-Dihydrocadambine
  • HY-121653B
    Flesinoxan hydrochloride

    DU-29373

    		 5-HT Receptor Neurological Disease
    Flesinoxan hydrochloride is a hypotensive agent and a potent, high affinity and selective 5-hydroxytryptamine1A (5-HT1A) receptor agonist with an EC50 value of 24 nM. Flesinoxan hydrochloride also has effective anxiolytic/antidepressant effects .
    Flesinoxan hydrochloride
  • HY-163994
    Ibuterol hydrochloride

    KWD 2058 hydrochloride

    		 Others Others
    Ibuterol (KWD 2058) hydrochloride, a diester of Terbutaline (HY-B0802A), is an orally active, selective and effective β-stimulating agent with lipophilic activities. Ibuterol hydrochloride is also an orally active ocular hypotensive agent. Ibuterol hydrochloride relieves bronchial obstruction in asthma without causing circulatory effects. Ibuterol hydrochloride is proming for rasearch of intraocular hypertension, asthma and bronchitis .
    Ibuterol hydrochloride
  • HY-122215
    Tilisolol hydrochloride

    N-696

    		 Others Endocrinology
    Tilisolol hydrochloride (N-696) is a non-selective β-adrenergic antagonist with vasodilatory and hypotensive activities. Tilisolol hydrochloride exerts its effects in canine coronary arteries by opening ATP-sensitive K+ channels. Tilisolol hydrochloride exhibits concentration-dependent relaxation in KCl-precontracted rat thoracic aorta. Tilisolol hydrochloride reduces diastolic blood pressure in a dose-dependent manner and slightly increases heart rate in spinal cord stimulated rats .
    Tilisolol hydrochloride
  • HY-129934
    Latanoprost ethyl amide

    Lat-NEt

    		 Prostaglandin Receptor Endocrinology
    Latanoprost ethyl amide (Lat-NEt) is a latanoprost analog in which the C-1 carboxyl group has been modified to an N-ethyl amide. Prostaglandin esters have been shown to have ocular hypotensive activity.1 Prostaglandin N-ethyl amides were recently introduced as alternative prostaglandin ocular hypotensive prodrugs. Although it has been claimed that prostaglandin ethyl amides are not converted to the free acids in vivo, studies in our laboratories have shown that bovine and human corneal tissue converts the N-ethyl amides of various prostaglandins to the free acids with a conversion rate of about 2.5 μg/g corneal tissue/hr. Lat-NEt would be expected to show the typical intraocular effects of Latanoprost free acid, but with the much slower hydrolysis pharmacokinetics of the prostaglandin N-amides.
    Latanoprost ethyl amide
  • HY-19145
    PD-134672

    CI-992

    		 Renin Cancer
    PD-134672 (CI-992) is a renin inhibitor containing a 2-amino-4-thiazolyl substituent. PD-134672 potently inhibits monkey renin in vitro and only weakly inhibits the related aspartic protease bovine feline hepsin D. The compound exhibits oral hypotensive activity in hyperreninemic normotensive monkeys. Based on its superior efficacy and long-lasting effects in vitro and in the normotensive macaque model, PD-134672 was selected for further evaluation in renal hypertensive monkeys.
    PD-134672
  • HY-155297
    Nebidrazine

    FLA-136

    		 Histamine Receptor Cardiovascular Disease
    Nebidrazine is a centrally-acting hypotensive agent compared to clonidine, demonstrating weaker cardiovascular effects in rats. It induces dose-dependent hypotension and bradycardia when administered intracerebroventricularly (i.c.v.), with significantly lower sedative potential than clonidine in conscious rats. Yohimbine attenuates the cardiovascular effects of both Nebidrazine and clonidine, suggesting involvement of central alpha-autoreceptors sensitive to yohimbine. Unlike clonidine, Nebidrazine does not affect peripheral alpha-adrenoceptors in pithed rats, indicating a selective central mechanism. Chemical sympathectomy reduces Nebidrazine's cardiovascular effects more than clonidine's, and metiamide diminishes responses to both drugs, implicating central histamine receptors. These findings highlight Nebidrazine's distinct pharmacological profile and potential therapeutic application in managing hypertension through central alpha-autoreceptor stimulation .
    Nebidrazine
  • HY-136625
    LY134046

    		Others Neurological Disease
    LY134046 is an inhibitor of norepinephrine N-methyltransferase (NMT). Its cardiovascular activity was studied in anesthetized spontaneously hypertensive rats (SHR). Acute intraperitoneal injection of 10 and 20 mg/kg of LY134046 caused minimal cardiovascular changes, while 40 mg/kg resulted in a sustained decrease in mean arterial blood pressure and heart rate. This hypotension and bradycardia occurred rapidly and occurred when brain NMT activity was significantly inhibited. However, norepinephrine concentrations in rat brains were not significantly reduced at the time when LY134046-induced blood pressure and heart rate effects were maximal. The acute cardiovascular activity of LY134046 was not significantly affected by pretreatment of SHR with phentolamine, propranolol, or atropine, and LY134046 reduced heart rate in suspended SHR. In addition, acute or chronic administration of LY134046 did not antagonize the vasoconstrictor responses induced by sympathetic nerve stimulation or exogenous norepinephrine. These observations suggest that LY134046 does not interact with adrenergic or cholinergic receptors and that its hypotensive and bradycardic effects do not require neurogenic tension. Chronic intraperitoneal administration of LY134046 (40 mg/kg/day) resulted in a sustained and significant inhibition of hypothalamic and brainstem NMT activity, leading to central norepinephrine depletion. During chronic treatment, norepinephrine and dopamine concentrations increased in the brainstem and hypothalamus of SHR. Despite chronic inhibition of central NMT and norepinephrine depletion, cardiovascular parameters in SHR treated groups were not significantly different from those in saline-injected controls. Chronic treatment with LY134046 did not result in tolerance to its central biochemical effects or acute cardiovascular activity. The present study does not support the idea that norepinephrine-producing neurons are involved in the central regulation of cardiovascular function, because the hypotension and bradycardia induced by acute administration of LY134046 occurred before a significant decrease in hypothalamic norepinephrine concentrations, whereas chronic inhibition of central NMT and depletion of norepinephrine resulted in minimal changes in baseline cardiovascular parameters.
    LY134046
  • HY-137504
    20-ethyl Prostaglandin F2α

    ICI 74205; 20-ethyl PGF2α

    		 Prostaglandin Receptor Metabolic Disease
    20-ethyl Prostaglandin F2α (20-ethyl PGF2α) is an analog of PGF2α in which the ω-chain has been extended by the addition of two more methylene carbon atoms. It is therefore a modified version of the clinically approved glaucoma medication unoprostone.noprostone also contains lower side chain modifications (13,14-dihydro-15-keto) which severely limit its affinity for FP receptors, contributing to its lack of potency as a medication. 20-ethyl PGF2α retains the natural 15(S) allylic hydroxyl in the lower side chain, which may improve its potency as an intraocular hypotensive agent compared to unoprostone. The 2 carbon extension in 20-ethyl-PGF2α increases the Ki (120 nM) for the FP receptor from bovine corpus luteum only about 2.5-fold compared to PGF2α (50 nM).2 In vivo effects may be prolonged using 20-ethyl PGF2α, as the activity of 15-hydroxy PGDH using 20-ethyl PGF2α as a substrate is only 35% of the activity observed with PGF2α.
    20-ethyl Prostaglandin F2α

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: